Prelude Therapeutics Advances Cancer Treatment with Ongoing PRT7732 Study

Prelude Therapeutics is conducting a Phase 1 study to assess the safety and efficacy of PRT7732, an oral drug designed to degrade SMARCA2, in patients with advanced or metastatic solid tumors carrying a SMARCA4 mutation. The study aims to evaluate the drug's effectiveness in targeting tumors with SMARCA4 mutations and will influence Prelude Therapeutics' stock performance positively if preliminary results are favorable. The study is ongoing and recruiting participants, with the last update submitted on July 22, 2025.